Voyager Therapeutics, Inc.
NASDAQ: VYGR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alfred W. Sandrock Jr.
- Employees
- 172
- Headquarters
- Lexington, United States
- IPO year
- 2015
- Market cap
- $222.4M
- Website
- https://www.voyagertherapeutics.com
Loading VYGR…
Loading profile data…Frequently asked questions about VYGR
What does Voyager Therapeutics, Inc. (VYGR) do?
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfoli...
Where does VYGR trade?
Voyager Therapeutics, Inc. (VYGR) trades on the NASDAQ Global Select.
What sector is VYGR in?
Voyager Therapeutics, Inc. (VYGR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Voyager Therapeutics, Inc.?
Alfred W. Sandrock Jr. is the chief executive officer of Voyager Therapeutics, Inc. (VYGR).
Where is Voyager Therapeutics, Inc. headquartered?
Voyager Therapeutics, Inc. is headquartered in United States.
Does VYGR pay a dividend?
Voyager Therapeutics, Inc. (VYGR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VYGR go public?
Voyager Therapeutics, Inc. (VYGR) completed its initial public offering in 2015.